Peer education program for substance use and gender inclusion in Southern Africa

Peer Education for Gender Inclusion and Substance Use in Southern Africa (PEGISUS): A Pilot Trial Testing a Peer-based Intervention in Vocational Training Programs

Not applicable Interventional University Hospital, Basel, Switzerland · NCT06489899

This study is testing a peer education program to see if it can help young people in Southern Africa reduce substance use and challenge traditional gender beliefs.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment264 (estimated)
Ages16 Years to 24 Years
SexAll
SponsorUniversity Hospital, Basel, Switzerland Academic / other
Locations3 sites (Cape Town, Western Cape and 2 other locations)
Trial IDNCT06489899 on ClinicalTrials.gov

What this trial studies

This trial evaluates the effectiveness of a behavioral peer group intervention called PEGISUS, which focuses on substance use and gender equitable beliefs among adolescents and young adults in Zambia, Zimbabwe, and South Africa. The intervention will be integrated into existing vocational training programs and consists of nine sessions aimed at addressing substance use and traditional gender norms. Participants will be assessed at baseline, 12 weeks, and 24 weeks to measure the impact of the intervention compared to a standard care control group. The study aims to improve health outcomes by targeting peer influences and gender beliefs during a critical developmental period.

Who should consider this trial

Good fit: Ideal candidates are adolescents and young adults aged 16 to 24 who report regular substance use and are engaged in vocational training programs.

Not a fit: Patients with untreated major mental illnesses that interfere with participation may not benefit from this intervention.

Why it matters

Potential benefit: If successful, this intervention could significantly reduce substance use and promote gender equity among young people in Southern Africa.

How similar studies have performed: Other studies have shown success in peer-led interventions targeting substance use and gender norms, suggesting a promising approach for this population.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adolescents and young adults 16 - 24 years old
* At least weekly self-reported alcohol/drug use in a peer group in the past month or at least monthly heavy episodic drinking with peers over the past three months
* Comfortable communicating in the predominant local language or English
* Lives in the target community and plans to remain in the area for the next 12 months
* Eligible to participate in the vocational training (VT) program (according to the VT program's own entry guidelines) and willing to participate in the entirety of the program
* Interested to participate in a substance reduction and gender equity beliefs program and able to identify 2 to 5 peers to join
* Willing to have PEGISUS workshop sessions audio/video-recorded (if assigned to that group)

Exclusion Criteria:

* Untreated major mental illness that interferes with study participation, such as active suicidality, or unmanaged bipolar disorder or psychotic disorder
* Currently receiving psychological treatment for substance use
* Participation in another VT/skills development program or another trial that is judged by the site investigator as non-compatible with this study
* Unable to provide informed consent or informed assent

Where this trial is running

Cape Town, Western Cape and 2 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Substance UseGender Rolegendersubstance useZimbabweZambiaSouth Africa
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.